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The Editorial on the Research Topic
In silico Modeling of Brain Receptors for Antidepressants, Psychostimulants, and Other
CNS-Active Drugs
The physiological binding sites for antidepressants, antipsychotics, psychostimulants, opiates, and
anticonvulsants are embedded in the membranes of neurons and their vesicles. Such integral
membrane proteins (IMPs) have been notoriously difficult to crystallize in situ (Bolla et al., 2012),
and extracting the proteins from the membrane before crystallization may render a nonfunctional
protein. For decades, the dearth of precise structural information on IMP receptors and channels
in the CNS hindered understanding of their 3D structures and mechanisms of action, as well as
development of new medications. Computational tools for in silico (“virtual”) modeling of drug
receptors have been available since the early 1980s, yet their output could only be as accurate as the
known protein structure. More recently, breakthroughs related to IMP structure and function have
yielded high-resolution x-ray data for G protein-coupled receptors, voltage- and ligand-gated ion
channels, and neurotransmitter transporter proteins. These structures are finally providing credible
templates on which to build IMP computational models.
The seven articles in this special issue involve IMPs that control “gating” of substrates and/or
ions across the lipid bilayer. Passage of substrates/ions through a hydrophilic pore created by
IMP transmembrane helices is dependent on whether the channel is in an “open” or “closed”
conformation. These articles reflect the power of today’s computational methods to characterize
discrete transporter or channel conformations and the mechanisms by which they bind ligands
or interconvert between conformations. Characterization of discrete conformations with virtual
models is essential to assess substrate/ion translocation, the ligand-receptor interaction, and to
predict drug candidates.
Six articles focus on the “secondary active transporter” class of IMPs. Primary active transporters
require an energy source such as ATP hydrolysis to drive transmembrane passage of substrates
or ions against their concentration gradients (“uphill”). Secondary active transporter proteins,
in contrast, move the substrate uphill by simultaneously transporting one or more ion cofactors
“downhill,” providing the energy for transport. In the course of the substrate translocation cycle,
a transporter conformation with the substrate/ion permeation pore open to the extracellular space
(outward-facing; OF) interconverts with a conformation open to the cytoplasm (inward-facing; IF).
There may be intermediate conformations as well, depending on the transporter protein.
Surratt and Madura Computational Modeling of Drug Receptors
Five of the six secondary active transporter articles deal
with plasma membrane transporters for the monoamine
neurotransmitters dopamine, norepinephrine and serotonin,
best known as the targets of antidepressant drugs including
citalopram (Celexa™) and duloxetine (Cymbalta™). Our
understanding of human monoamine transporter (hMAT)
structure and function surged forward with crystal structures for
the distantly homologous bacterial leucine transporter (LeuT;
Yamashita et al., 2005) and the Drosophila dopamine transporter
(dDAT; Penmatsa et al., 2013) from Eric Gouaux and colleagues.
Models presented in all five issue articles employed Gouaux
structures as templates. Molecular dynamics (MD) simulations
of MAT recognition of substrates, inhibitors and ion cofactors
that drive transport, as well as the translocation mechanism
itself, are reviewed (Grouleff et al.). MD visualizes each atomic
shift of the protein as the external gating residues close behind
the entering substrate/ions, triggering opening of the internal
gate and movement of substrate and cofactors into the cell. A
second review article compares binding of structurally dissimilar
substrates and inhibitors in the primary substrate (S1) pockets
of dDAT, the three hMATs, and LeuBAT, the latter a LeuT
mutant protein in which the S1 pocket residues of LeuT have
been replaced with their human serotonin transporter (hSERT)
counterparts (Koldsø et al.). The ligand binding orientations
in S1 predicted from the models are in close agreement with
previously reported in vitro binding data.
A dDAT-based homology model of the OF conformation of
hDAT was used to predict the activity of a drug never before
tested as a DAT ligand (Cheng et al.). Using MD to follow
the movement of the anticholinergic drug orphenadrine within
the DAT model, the drug behaved much like the competitive
DAT inhibitor cocaine, and unlike the DAT substrates dopamine
and amphetamine. The MD prediction for orphenadrine was
confirmed by in vitro pharmacologic and cell biologic assays.
In reviewing MAT model-guided drug design (Mortensen and
Kortagere), the authors mention their own studies on identifying
an allosteric hSERT binding pocket and using the pocket to
screen a small molecule virtual library. Hit compounds retrieved
by the model were found to modulate SERT interactions
with serotonin, antidepressants, and psychostimulants. The
emerging field of fragment-based drug design (FBDD) is also
reviewed in the context of an hSERT model (as well as a
dopamine D3 receptor model) in this issue (Wasko et al.).
FBDD here entails the use of “virtual medicinal chemistry”
algorithms to build novel ligands from within the receptor
binding site. The sixth secondary active transporter article
(Vergara-Jaque et al.) differs from the previous five in that
the transporter class, represented by the glutamate transporter
GltPh, requires the substrate binding pocket itself to move as a
piston, or elevator, while interconverting between the OF and
IF conformations. Using repeat-swap homology modeling, the
authors successfully generate an OF model of the concentrative
nucleoside transporter VcCNT using as template the opposite
(IF) conformation of the nonhomologous GltPh protein that
shares its asymmetrical structure. The final article of the issue
explores the hydrophobic effect as a gating mechanism for the
K+ channel KcsA (Yonkunas and Kurnikova). Virtual KcsA
mutations were employed to model the transition between the
closed and open channel states.
Virtual screening with IMP models allows for discovery
of novel or repurposed drugs unlikely to be found using a
conventional SAR approach, providing “needle in a haystack”
lead compounds that would take considerably more time and
money to find with in vitro pharmacologic high-throughput
screens. Computational models allow academic laboratories
and similar small-budget enterprises to participate in drug
discovery. Atomistic and coarse-grained MD simulations allow
investigation of IMP conformational changes during receptor
activation or substrate/ion movement through a membrane
channel. The articles within reflect the cutting edge of in silico
approaches for understanding brain receptor mechanisms of
action, orientation of ligands within the receptor, and virtual
discovery of novel lead compound therapeutics.
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